New York urged to avoid increasing health care costs.
A federal program designed to offer prescription drug discounts to support underserved patients has been increasingly exploited by large hospitals, resulting in higher healthcare costs for employers and families while failing to deliver its intended benefits to the patients in need. This misuse has sparked a call for greater transparency and the implementation of targeted reforms to address the program’s disproportionate expansion. A recent report issued by the American Benefits Council highlights these concerns, particularly in relation to the 340B Drug Pricing Program.
Despite its objective to assist vulnerable populations, the 340B program has become a significant profit avenue for large healthcare institutions. Hospitals acquire prescription medications at substantial discounts, subsequently billing health plans at full price and retaining the differences. The financial implications are substantial, as reported hospital drug purchases through the 340B program skyrocketed from billion in 2010 to an astounding billion in 2023. This increase can be attributed to a vast expansion of contract pharmacy arrangements associated with the program. Alarmingly, many of these contracted pharmacies are situated in affluent regions, contrary to the program’s mission of serving socioeconomically disadvantaged neighborhoods.
The implications of unchecked growth in the 340B program extend beyond mere financial profit; they contribute to rising healthcare costs for families and employers. The heightened demand for expensive medications and the resultant hospital consolidations shift care to more costly environments, leaving many with increasing healthcare expenses. A recent analysis by IQVIA revealed that state employee health plans faced approximately million in annual 340B-related overcharges on self-administered medications. Each patient incurred a heightened spending of 7 due to a staggering 146% markup, ultimately impacting the affordability of health coverage for many working families.
The current trajectory of the 340B program, without significant reforms, poses a direct threat to New York’s stated goals of healthcare affordability. The state Senate’s recent budget proposal, which may perpetuate a lack of transparency in the 340B program, further complicates matters. It emphasizes the need for legislative measures aimed at revealing how hospitals utilize their 340B revenues—ensuring that these funds benefit the intended patients rather than bolstering the profits of large health systems.
As negotiations concerning the state budget progress, it is crucial for lawmakers to prioritize meaningful reforms that enhance healthcare affordability. Employers and advocates alike support the program’s foundational intent, which is to provide vital assistance to those most in need. To achieve this, Congress must implement reforms that ensure the program functions as intended, ultimately safeguarding the resources for underserved patients without imposing excess financial burdens on employers and working families.
